These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 23064955)

  • 41. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
    Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
    Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
    Luo H; Yu Z; Gao H; Guan C; Xu M
    J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
    Kodera Y; Ito S; Mochizuki Y; Kondo K; Koshikawa K; Suzuki N; Kojima H; Kojima T; Matsui T; Takase T; Tsuboi K; Fujiwara M; Nakao A;
    Eur J Surg Oncol; 2009 Nov; 35(11):1158-63. PubMed ID: 19328643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
    Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
    Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of biweekly docetaxel and S-1 combination chemotherapy for advanced gastric cancer.
    Kunisaki C; Takahashi M; Nagahori Y; Makino H; Takagawa R; Sato T; Oshima T; Fujii S; Kosaka T; Ono HA; Akiyama H; Shimada H
    Anticancer Res; 2008; 28(4C):2473-8. PubMed ID: 18751437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer.
    Kurt E; Cubukcu E; Karabulut B; Olmez OF; Kurt M; Avci N; Ozdemir F; Tunali D; Evrensel T; Manavoglu O
    J BUON; 2013; 18(1):147-53. PubMed ID: 23613400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
    Yanagihara K; Yoshimura K; Niimi M; Yasuda H; Sasaki T; Nishimura T; Ishiguro H; Matsumoto S; Kitano T; Kanai M; Misawa A; Tada H; Teramukai S; Mio T; Fukushima M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):913-8. PubMed ID: 20069422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
    Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
    Kim H; Park JH; Bang SJ; Kim DH; Cho HR; Kim GY; Min YJ
    Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Takayama T; Sato Y; Sagawa T; Okamoto T; Nagashima H; Takahashi Y; Ohnuma H; Kuroiwa G; Miyanishi K; Takimoto R; Matsunaga T; Kato J; Yamaguchi K; Hirata K; Niitsu Y
    Br J Cancer; 2007 Oct; 97(7):851-6. PubMed ID: 17848958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
    Oh DY; Kim TY; Kwon JH; Lee JJ; Joh Y; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Jul; 35(7):380-5. PubMed ID: 15976069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.